NEWS

    2022
    01-01
    The establishment of Credo Diagnostics Biomedical Pte. Ltd. Taiwan Branch for delivering the highest quality medical solutions

    Taiwan, January 1, 2022 –It is with great pleasure that we announce the establishment of our Branch in the Republic of China, Taiwan. This important milestone comes as part of our continuous efforts to expand our reach and make our products and services as widely available as possible. Importantly, this initiative continues our focus, ADVANCED MEDTECH FOR ALL.

    The choice of Taiwan is very clear.

    “As a member of international organisations such as the World Trade Organisation (WTO) and the Asia Pacific Economic Cooperation (APEC), Taiwan is highly free in economic activities. Coupled with its economic stability and measures being taken to cut red tape and remove bureaucracy from business procedures, it was an easy decision”, said Dr. Winston Wong Jr., Chairman and CEO of Credo Diagnostics Biomedical.

    “Besides, Taiwan has demonstrated that their diversified pool of biotech talents has high-quality standards. In addition to their outstanding medical system, Taiwan offers a comprehensive supply chain for the biomedical industry. Taking advantages of the many business friendly offerings in Taiwan, Credo Diagnostics aims to provide excellent and accurate medical solutions to improve the lives of people around the world.”

     


    About Credo Diagnostics Biomedical Pte. Ltd.

    Credo Diagnostics develops and manufactures innovative, easy-to-use and rapid molecular diagnostic solutions for Point-of-Care (POC) applications at affordable costs without compromising accuracy and speed in the areas Human Health. Leveraging solid and established science, combined with efficient integration and strategic innovation, Credo Diagnostics Biomedical provides advanced medical technologies for all.


    Media Contact:
    Cheryl Yang
    Tel: +886 2-2697-3998 Ext.1116
    Email: cheryl.yang@credodxbiomed.com

     

    view more
    2021
    12-22
    Credo Diagnostics is proud to be one of the Top 50 Healthcare Startups in Singapore!

    Singapore, December 22, 2021 – Credo Diagnostics is proud to be on the list of “Top 50 Healthcare Startups in Singapore” published by StartupLanes. We vow to accelerate the molecular test and provide it at an affordable cost. Being on the list of Top 50 Healthcare Startups is a great reward to our efforts and our pursuit to the mission “Advanced Medtech for All” will never stop.

    Read more details:https://lnkd.in/gui6iSa2


    About StartupLanes

    StartupLanes is an ecosystem for Startups and Investors. Collaborate or find a co-founder, it’s a platform for Entrepreneurs. We love startups! A place for Angel Investors and Venture Capitalists to find investing opportunities in startups. Validate your idea, Learn & Execute.StartupLanes offers dedicated Investment Banking services for startups. No Retainer Fee, Only Activation, and Success Fee.

     


    About Credo Diagnostics Biomedical Pte. Ltd.

    Credo Diagnostics develops and manufactures innovative, easy-to-use and rapid molecular diagnostic solutions for Point-of-Care (POC) applications at affordable costs without compromising accuracy and speed in the areas Human Health. Leveraging solid and established science, combined with efficient integration and strategic innovation, Credo Diagnostics Biomedical provides advanced medical technologies for all.

    view more
    2021
    12-21
    Credo VitaPCR™ SARS-CoV-2 RNA detection Assay can correctly detect the new Omicron strain B.1.1.529 BA.1 and its sublineage BA.2 (stealth version)

    Singapore, December 21, 2021 – In response to the new Omicron variant (also known as B.1.1.529), we, Credo Diagnostics Biomedical Pte Ltd, have performed the BLASTn analysis (with the oligonucleotide primers and probes of the assays involving SARS-CoV-2 detection) against the sequences listed in GISAID on December 17th, 2021.

     

    According to our analysis, we confirm that our SARS-CoV-2 RNA detection assay is capable of correctly detecting the new Omicron strain, including B.1.1.529 BA.1 and BA.2.

     

    Meanwhile. we continue to affirm that our SARS-CoV-2 RNA detection assay is still capable of detecting the following earlier variant strains correctly

     

    Another four Variants of Concern (VOC):

    Alpha variant: known as B.1.1.7

    Beta variant: known as B.1.351

    Gamma variant: known as P.1

    Delta variant: known as B.1.617.2

     

    Two Variants of Interest (VOI):

    Lambda variant: known as C.37

    Mu variant: known as B.1.621

     

    The other six variants:

    Eta variant: known as B.1.525

    Iota variant: known as B.1.526

    Kappa variant: known as B.1.617.1

    Zeta variant: known as P.2

    Epsilon variant: known as B.1.427/B.1.429

    Indian variant: known as B.1.617.3


    About Credo Diagnostics Biomedical Pte. Ltd.

    Credo Diagnostics develops and manufactures innovative, easy-to-use and rapid molecular diagnostic solutions for Point-of-Care (POC) applications at affordable costs without compromising accuracy and speed in the areas Human Health. Leveraging solid and established science, combined with efficient integration and strategic innovation, Credo Diagnostics Biomedical provides advanced medical technologies for all.

    view more
    2021
    12-01
    The Change of Address

    Credo Diagnostics develops and manufactures innovative, easy-to-use and rapid molecular diagnostic solutions for Point-of-Care (POC) applications at affordable costs without compromising accuracy and speed in the areas Human Health. Leveraging solid and established science, combined with efficient integration and strategic innovation, Credo Diagnostics Biomedical provides advanced medical technologies for all.

    view more
    2021
    11-29
    Analysis Shows Credo’s VitaPCR™ SARS-CoV-2 Related Assays are capable of detecting the new variant strain Omicron Variant correctly

    Analysis Shows Credo’s VitaPCR™ SARS-CoV-2 Related Assays are capable of detecting the new variant strain Omicron Variant correctly.

    view more
    2021
    01-01